Re-sensitizing tumor cells to cancer drugs with epigenetic regulators.
Abstract Cancer drug resistance is a major problem for cancer therapy. While many drugs can be effective in first line treatments, cancer cells can become resistant due to genetic (mutations and chromosomal aberrations) but also epigenetic changes. Hence, many research studies addressed epigenetic drugs in circumventing resistance to conventional therapeutics in different tumor entities and in increasing efficiency of immune checkpoint therapies. Furthermore, repositioning of already approved drugs in combination with epigenetic modifiers could potentiate their efficacy and could thus be an attractive strategy for...
Source: Current Cancer Drug Targets - January 7, 2021 Category: Cancer & Oncology Authors: Rauscher S, Greil R, Geisberger R Tags: Curr Cancer Drug Targets Source Type: research

miRNA as regulators of prostate carcinogenesis and endocrine and chemoresistance.
Abstract More therapy options are available for advanced prostate cancer, including novel inhibitors of androgen synthesis, anti-androgens, chemotherapeutics and targeted therapies. Although patients´ survival has been improved, management of castration therapy-resistant prostate cancer remains a challenge. Regulation of cellular events in cancer by small non-coding miRNAs is therefore an area of special interest. Overexpression of selected miRNA may lead to androgen independence and prostate cancer progression. miRNA may be considered also a biomarker in patients with prostate cancer. In contrast, diminishe...
Source: Current Cancer Drug Targets - January 7, 2021 Category: Cancer & Oncology Authors: Culig Z Tags: Curr Cancer Drug Targets Source Type: research

LncRNAs as an Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy.
Abstract Long non-coding RNAs (LncRNAs) epitomize a class of non-coding regulatory RNAs with more than 200 nucleotides long and situated in the nucleus or cytoplasm and rarely encode proteins. Accruing evidence signposts that lncRNAs act as molecular switches in different cellular activities like differentiation, apoptosis as well as reprogramming of cellular states by modifying gene expression patterns. The revelation of immense numbers of lncRNA with their widespread variety of expression patterns in different kinds of malignancy, tumor explicitness and their steadiness in circulating body fluids deliver an inno...
Source: Current Cancer Drug Targets - January 6, 2021 Category: Cancer & Oncology Authors: Ray SK, Mukherjee S Tags: Curr Cancer Drug Targets Source Type: research

Epigenetic mechanisms of therapy resistance in diffuse large B cell lymphoma (DLBCL).
Abstract Diffuse large B cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin B cell lymphoma (NHL), and manifest highly heterogeneous genetic/phenotypic characteristics as well as variable responses to conventional immunochemotherapy (1). Genetic profiling of DLBCL patients has revealed highly recurrent mutations of epigenetic regulator genes such as CREBBP, KMT2D, EZH2 and TET2. These mutations drive malignant transformation by through aberrant epigenetic programming of B-cells and may influence clinical outcomes (2-4). These and other chromatin modifier genes also play critical roles in ...
Source: Current Cancer Drug Targets - January 6, 2021 Category: Cancer & Oncology Authors: Isshiki Y, Melnick A Tags: Curr Cancer Drug Targets Source Type: research

Acid ceramidase, a double-edged sword in cancer aggression: A minireview.
Abstract Acid ceramidase (AC), the key enzyme of the ceramide metabolic pathway hydrolyzes pro-apoptotic ceramide to sphingosine, which by the action of sphingosine-1-kinase is metabolized to mitogenic sphingosine-1-phosphate. The intracellular level of AC determines ceramide/sphingosine-1-phosphate rheostat which in turn decides the cell fate. The upregulated AC expression during cancerous condition acts as a "double-edged sword" by converting pro-apoptotic ceramide to anti-apoptotic sphingosine-1-phosphate, wherein on one end, the level of ceramide is decreased and on the other end, the level of sphing...
Source: Current Cancer Drug Targets - December 23, 2020 Category: Cancer & Oncology Authors: Vethakanraj HS, Chandrasekaran N, Sekar AK Tags: Curr Cancer Drug Targets Source Type: research

Expression and clinical significance of SARS-CoV-2 human targets in neoplastic and non-neoplastic lung tissues.
CONCLUSIONS: Comprehensive molecular analyses revealed a heterogeneous and distinct expression and/or methylation profile of ACE2 and TMPRSS2 in healthy lung vs. LUAD tissues across sex, age and smoking history and might have implications for COVID-19 disease. PMID: 33292131 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - December 7, 2020 Category: Cancer & Oncology Authors: Subbarayan K, Ulagappan K, Wickenhauser C, Seliger B Tags: Curr Cancer Drug Targets Source Type: research

Targeted biological effect of an affitoxin composed of an HPV16E7 affibody fused with granzyme B (ZHPV16E7-GrB) against cervical cancer in vitro and in vivo.
CONCLUSIONS: The affitoxin by coupling the affibody with GrB is a promising targeted therapeutic agent with the dual advantages of the targeted affibody and the GrB cytotoxin. PMID: 33292132 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - December 7, 2020 Category: Cancer & Oncology Authors: Wang W, Tan X, Jiang J, Cai Y, Feng F, Zhang L, Li W Tags: Curr Cancer Drug Targets Source Type: research

Forkhead-box A3 (FOXA3) represses cancer stemness and partially potentiates chemosensitivity by targeting metastasis-associated in colon cancer 1 (MACC1) signaling pathway in colorectal cancer cells.
CONCLUSION: Our findings establish FOXA3 as a potent tumor suppressor in CRC, which may disrupt the maintenance of stemness and modulate sensitivity to oxaliplatin by inhibiting the transcription of MACC1 within CRC cells. PMID: 33292133 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - December 7, 2020 Category: Cancer & Oncology Authors: Li N, Li Y, Gao H, Li J, Ma X, Liu X, Gong P, Cui X, Li Y Tags: Curr Cancer Drug Targets Source Type: research

Modulation of Matrix Metalloproteinases by Plant-Derived Products.
Abstract Matrix metalloproteinases (MMPs) are a group of zinc-dependent metallo-endopeptidase that are responsible towards the degradation, repair and remodelling of extracellular matrix components. MMPs play an important role in maintaining a normal physiological function and preventing diseases such as cancer and cardiovascular diseases. Natural products derived from plants have been used as traditional medicine for centuries. Its active compounds, such as catechin, resveratrol and quercetin, are suggested to play an important role as MMPs inhibitors, thereby opening new insights into their applications in many ...
Source: Current Cancer Drug Targets - November 20, 2020 Category: Cancer & Oncology Authors: Anuar NNM, Zulkafali NIN, Ugusman A Tags: Curr Cancer Drug Targets Source Type: research

Concomitant expression of inhibitory molecules for T cell activation predicts poor survival in patients with esophageal squamous cell carcinoma.
Abstract BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a major subtype of esophageal cancers. The Five-year survival rate of ESCC is low and molecular targets for ESCC treatment and prognosis assessment are very limited. T cells are critical for clearance of cancer cells and blockade of co-inhibitory molecules for T cell activation has emerged as a promising therapy to treat cancer patients. However, in ESCC patients such co-inhibitory molecules regulating T cell activation is poorly documented. OBJECTIVE: We aim to evaluate how the presence of inhibitory check-point molecules in T cells could impa...
Source: Current Cancer Drug Targets - November 20, 2020 Category: Cancer & Oncology Authors: Chen Z, Cao K, Zhang J, Liu Z, Lu L, Qi B, Shi L, Huang R, Zhao S Tags: Curr Cancer Drug Targets Source Type: research

Paclitaxel Priming of TRAIL Expressing Mesenchymal Stromal Cells (MSCs-TRAIL) Increases Antitumor Efficacy of Their Secretome.
CONCLUSIONS: Our result is the first demonstration of the possible merging of two new MSCs therapy approaches based on genetic manipulation and drug delivery. If confirmed in vivo, this could potentiate the efficacy of MSCs-TRAIL and strongly contribute to reduce the toxicity due to the systemic treatment of PTX. PMID: 33200709 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 15, 2020 Category: Cancer & Oncology Authors: Coccè V, Bonomi A, Cavicchini L, Sisto F, Giannì A, Farronato G, Alessandri G, Petrella F, Sordi V, Parati E, Bondiolotti G, Paino F, Pessina A Tags: Curr Cancer Drug Targets Source Type: research

Selective Antitumor Effect of Shikonin Derived DMAKO-20 on Melanoma through CYP1B1.
CONCLUSION: DMAKO-20 exhibited a selective cytotoxic effect on melanoma cells through CYP1B1-mediated activation. Using DMAKO-20 as a lead compound, further structural optimization may provide new drug entities for the treatments of malignant skin carcinomas. PMID: 33200710 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 15, 2020 Category: Cancer & Oncology Authors: Cui J, Zhou X, Huang J, Cui J, Chen J Tags: Curr Cancer Drug Targets Source Type: research

MUC glycoproteins: Potential biomarkers and molecular targets for cancer therapy.
Abstract MUC proteins have great significance as prognostic and diagnostic markers as well as a potential target for therapeutic interventions in most cancers of glandular epithelial origin. These are high molecular weight glycosylated proteins located in the epithelial lining of several tissues and ducts. Mucins belong to a heterogeneous group of large O-glycoproteins that can be either secreted or membrane-bound. Glycosylation, a post-translational modification affects the bio-physical, functional and biochemical properties and provides structural complexity for these proteins. Aberrant expression and glycosylat...
Source: Current Cancer Drug Targets - November 15, 2020 Category: Cancer & Oncology Authors: Ratan C, Cicily K D D, Nair B, Nath LR Tags: Curr Cancer Drug Targets Source Type: research

Potential Role of miRNA in Mestastatic Cascade of Triple Negative Breast Cancer.
Abstract Triple negative breast cancer present aggressive form of breast cancer subtype which further lacks efficient treatment strategies and prognostic markers. Genomic heterogeneity in TNBC has led to the relapse of tumor and cancer stem cells with higher likelihood of distal metastasis. Several studies supported the notion that miRNAs may act as oncogene or tumor suppressors in TNBC. miRNAs may function as global regulator of TNBC by targeting post transcriptional regulation of several genes involved in influencing metastatic events but the exact mechanism involved in inducing the effect is yet to be elucidate...
Source: Current Cancer Drug Targets - November 3, 2020 Category: Cancer & Oncology Authors: Balkrishna A, Mittal R, Arya V Tags: Curr Cancer Drug Targets Source Type: research

Management of Prostate Cancer with Systemic Therapy. A Prostate Cancer Unit Perspective.
Abstract The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs and new treatment options. To update the background knowledge of shared uro-oncologic practice, we reviewed current statements and landmarks in systemic therapy. A number of new agents are under investigation in non-metastatic and metastatic disease. Similarly, new target imaging technologies are under development to improve the detection rate of true non-metastatic and true metastatic patient. Five new drugs have shown to be effective on progression-free and overall survival in metastatìc prostate cancer. Howe...
Source: Current Cancer Drug Targets - October 21, 2020 Category: Cancer & Oncology Authors: Campodonico F, Ennas M, Zanardi S, Zigoura E, Piccardo A, Foppiani L, Schiavone C, Squillace L, Benelli A, De Censi A, Grillo-Ruggieri F, Introini C Tags: Curr Cancer Drug Targets Source Type: research

C-Myc signaling pathway in treatment and prevention of brain tumors.
Abstract Brain tumors are responsible for high morbidity and mortality worldwide. Several factors such as the presence of blood-brain barrier (BBB), sensitive location in the brain, and unique biological features challenge the treatment of brain tumors. The conventional drugs are no longer effective in the treatment of brain tumors, and scientists are trying to find novel therapeutics for brain tumors. In this way, identification of molecular pathways can facilitate finding an effective treatment. c-Myc is an oncogene signaling pathway capable of regulation of biological processes such as apoptotic cell death, pro...
Source: Current Cancer Drug Targets - October 16, 2020 Category: Cancer & Oncology Authors: Ashrafizadeh M, Zarabi A, Hushmandi K, Moghadam ER, Hashemi F, Daneshi S, Hashemi F, Tavakol S, Mohammadinejad R, Najafi M, Dudha N, Garg M Tags: Curr Cancer Drug Targets Source Type: research

Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: a Comprehensive Analysis.
Abstract Lung cancer is the leading type of cancer worldwide today. Kinases play a crucial role in mediating the signaling pathways and it directs to control several necessary cellular processes. Conversely, deregulation of tyrosine kinases leads to oncogenic conversion, uncontrolled cell proliferation and tumorigenesis. Tyrosine kinases are largely deregulated in lung cancer and specifically in non-small cell lung cancer (NSCLC). Therefore the inhibition of pathogenic kinases is a breakthrough development in cancer research, treatment and care, which clinically improves the quality of life. In the last decades va...
Source: Current Cancer Drug Targets - October 9, 2020 Category: Cancer & Oncology Authors: Murugesan S, Murugesan J, Palaniappan S, Palaniappan S, Murugan T, Siddiqui SS, Loganathan S Tags: Curr Cancer Drug Targets Source Type: research

Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients.
CONCLUSION: The status of RAD50 promoter's methylation inversely correlates with the expression level of RAD50. While RAD50 is overexpressed in breast cancer patients and thus makes tumor resistant against many anti-cancer drugs. PMID: 33038913 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - October 9, 2020 Category: Cancer & Oncology Authors: Karamat U, Ejaz S Tags: Curr Cancer Drug Targets Source Type: research

The activation of procarcinogens by CYP1A1/1B1 and related chemopreventive agents: A review.
Abstract CYP1A1 and CYP1B1 are extrahepatic P450 family members involved in the metabolism of procarcinogens, such as PAHs, heterocyclic amines and halogen-containing organic compounds. CYP1A1/1B1 also participate in the metabolism of endogenous 17-β-estradiol, producing estradiol hydroquinones which are the intermediates of carcinogenic semiquinones and quinones. CYP1A1 and CYP1B1 proteins share approximately half amino acid sequence identity but differ in crystal structures. As a result, CYP1A1 and CYP1B1 have different substrate specificity to chemical procarcinogens. This review will introduce the general...
Source: Current Cancer Drug Targets - October 6, 2020 Category: Cancer & Oncology Authors: Li Y, Cui J, Jia J Tags: Curr Cancer Drug Targets Source Type: research

Tumor penetrating peptide-functionalized Tenascin-C antibody for glioblastoma targeting.
CONCLUSION: The genetic fusion of iRGD tumor penetrating peptide to non-internalizing affinity targeting ligands may improve their tumor tropism and parenchymal penetration for more efficient delivery of imaging and therapeutic agents into solid tumor lesions. PMID: 33001014 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 30, 2020 Category: Cancer & Oncology Authors: Lingasamy P, Laarmann AH, Teesalu T Tags: Curr Cancer Drug Targets Source Type: research

Exosome as a Natural Gene Delivery Vector for Cancer Treatment.
CONCLUSION: In the near future exosomes can become an efficient gene carrier for delivery and a biomarker for the diagnosis and treatment of cancer. PMID: 32972340 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 23, 2020 Category: Cancer & Oncology Authors: Pofali P, Mondal A, Londhe V Tags: Curr Cancer Drug Targets Source Type: research

Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study.
CONCLUSIONS: Our results confirm the efficacy and safety of a first line regimen comprising gemcitabine and Nab-paclitaxel in metastatic PDAC in a real-life population. PMID: 32957885 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 17, 2020 Category: Cancer & Oncology Authors: Catalano M, Roviello G, Conca R, D'Angelo A, Palmieri VE, Panella B, Petrioli R, Ianza A, Nobili S, Mini E, Ramello M Tags: Curr Cancer Drug Targets Source Type: research

Identification of WDFY3 neoantigens as prognostic markers in long-term survivors of extrahepatic cholangiocarcinoma.
Abstract BACKGROUND: Neoantigens are newly formed antigens that have not been previously recognized by the immune system. They may arise from altered tumor proteins that form as a result of mutations. Although neoantigens have recently been linked to antitumor immunity in long-term survivors of cancers, such as melanoma and colorectal cancer, their prognostic and immune-modulatory role in many cancer types remains undefined. OBJECTIVE: The purpose of this study is to identify prognostic markers for long-term extrahepatic cholangiocarcinoma (EHCC) survival. METHODS: We investigated neoantigens in EHCC, a ...
Source: Current Cancer Drug Targets - September 17, 2020 Category: Cancer & Oncology Authors: Wang Y, Jin B, Zhou N, Sun Z, Li J, Chen Q, Wu X, Zhou Y, Shi Y, Lu X, Sang X, Mao Y, Du S, Wang W, Bai C Tags: Curr Cancer Drug Targets Source Type: research

ASPM predicts poor clinical outcome and promotes tumorigenesis for diffuse large B-cell lymphoma.
CONCLUSION: Collectively, our results suggested that ASPM potentially served as a predictive biomarker of DLCBL tumorigenesis and prognosis, representing a potential therapeutic target for DLCBL. PMID: 32933462 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 13, 2020 Category: Cancer & Oncology Authors: Wu J, He Z, Zhu Y, Jiang C, Deng Y, Wei B Tags: Curr Cancer Drug Targets Source Type: research

An Overview of promising Biomarkers in cancer screening and detection.
Abstract Applications of biomarkers have been proved in oncology screening, diagnosis, predicting response to treatment as well as monitoring the progress of disease. Considering the crucial role played by them during different disease stages, it is extremely important to evaluate, validate and assess them to incorporate them into routine clinical care. In this review, we address role of few most promising and successfully used biomarkers in cancer detection, i.e. PD-L1, E-Cadherin, TP53, Exosomes, cfDNA, EGFR, mTOR with regard to their structure, mode of action and reports signifying their pathological significan...
Source: Current Cancer Drug Targets - August 22, 2020 Category: Cancer & Oncology Authors: Hasan S Tags: Curr Cancer Drug Targets Source Type: research

Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy.
Abstract Normal cells must overcome multiple protective mechanisms to develop into cancer cells. Their new capabilities include self-sufficiency in growth signals and insensitivity to antigrowth signals, evasion of apoptosis, a limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis; these are also termed the six hallmarks of cancer. A deep understanding of the genetic and protein alterations involved in these processes has enabled the development of targeted therapy strategies and clinical trial design in the search for ovarian cancer treatments. Clinically, significantly longe...
Source: Current Cancer Drug Targets - August 15, 2020 Category: Cancer & Oncology Authors: Gong H, Nieb D, Lia Z Tags: Curr Cancer Drug Targets Source Type: research

Prognostic Value of miRNAs in Patients with Laryngeal Cancer: A Systematic Review and Meta-Analysis.
Abstract BACKGROUND: Many studies have explored the relationship between the expression level of miRNAs and the prognosis of patients with laryngeal cancer (LC). However, the prognostic value of miRNA in LC patients has not been comprehensively evaluated. METHODS: PubMed, Web of Science, Embase, and Cochrane Database of Systematic Reviews were extensively searched for all studies published before the end of February, 2020 that investigated the correlation between miRNA expression level and clinical prognosis in patients with LC. RESULTS: Twenty-one studies involving 1784 patients were included in our met...
Source: Current Cancer Drug Targets - August 4, 2020 Category: Cancer & Oncology Authors: Zou W, Hu X, Wang D, Jiang L Tags: Curr Cancer Drug Targets Source Type: research

Advances in Regulating Tumorigenicity and Metastasis of Cancer through TrkB Signaling.
Abstract The clinical pathology of various human malignancies is supported by tropomyosin receptor kinase (Trk) B TrkB which is a specific binding receptor of the brain-derived neurotrophic factor (BDNF).TrkB and TrkB fusion proteins have been observed to be over-expressed in many cancer patients. Moreover, they were observed in multiple types of cells. A few signaling pathways can be modulated by the abnormal activation of the BDNF/TrkB pathway. These signaling pathways in-clude PI3K/Akt pathway, transactivation of EGFR, phospholipase C-gamma(PLCγ) pathway, Ras-Raf-MEK-ERK path-way, Jak/STAT pathway, and nu...
Source: Current Cancer Drug Targets - July 29, 2020 Category: Cancer & Oncology Authors: Zou W, Hu X, Jiang L Tags: Curr Cancer Drug Targets Source Type: research

MALAT1 as a Versatile Regulator of Cancer: Overview of the updates from Predatory role as Competitive Endogenous RNA to Mechanistic In-sights.
Abstract Central dogma of molecular biology has remained cornerstone of classical molecular biology but serendipitous discovery of microRNAs (miRNAs) in nematodes paradigmatically shifted our current understanding of the intricate mech-anisms which occur during transitions from transcription to translation. Discovery of miRNA captured tremendous attention and appreciation and we had witnessed an explosion in the field of non-coding RNAs. Ground-breaking discoveries in the field of non-coding RNAs have helped in better characterization of microRNAs and long non-coding RNAs (LncRNAs). There is an ever-increasing lis...
Source: Current Cancer Drug Targets - July 29, 2020 Category: Cancer & Oncology Authors: Farooqi AA, Legaki E, Gazouli M, Rinaldi S, Berardi R Tags: Curr Cancer Drug Targets Source Type: research

Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN- γ Signaling.
CONCLUSION: PMQ could inhibit HCC progression in obese mice at least in part through down-regulating adipocytes-induced PD-L1 expression via IFN-γ signaling. PMID: 32748749 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - July 29, 2020 Category: Cancer & Oncology Authors: Li Z, Gao WQ, Wang P, Wang TQ, Xu WC, Zhu XY, Liu H Tags: Curr Cancer Drug Targets Source Type: research

Tumor-induced Metabolism and T Cells Located in Tumor Environment.
Abstract Several subtypes of T cells are located in a tumor environment, each of which supplies their energy using different metabolic mechanisms. Since the cancer cells require high levels of glucose, the conditions of food poverty in the tumor environment can cause inactivation of immune cells, especially the T-effector cells, due to the need for glucose in the early stages of these cells activity. Different signaling pathways such as PI3K-AKt-mTOR, MAPK, HIF-1α, etc active or inactive by the amount and type of energy source or oxygen levels that determine the fate of T cells in a cancerous environment. Th...
Source: Current Cancer Drug Targets - July 18, 2020 Category: Cancer & Oncology Authors: Iranparast S, Tayebi S, Ahmadpour F, Yousefi B Tags: Curr Cancer Drug Targets Source Type: research

Molecular Dynamics in Esophageal Adenocarcinoma: Who's in Control?
Abstract Esophageal adenocarcinoma (EAC) is one of the fastest-growing cancers in the world. It occurs primarily due to the chronic gastroesophageal reflux disease (GERD), during which the esophageal epithelium is frequently exposed to the acidic fluid coming up from the stomach. This triggers gene mutations in the esophageal cells, which may lead to EAC development. While p53 is activated to get rid of the mutated cells, NFB orchestrates the remaining cells to heal the wound. However, if the mutations happen to TP53 (a common occasion), the mutant product turns to support tumorigenesis. In this case, NFκ...
Source: Current Cancer Drug Targets - July 18, 2020 Category: Cancer & Oncology Authors: Dang T, Chai J Tags: Curr Cancer Drug Targets Source Type: research

Regulation of Breast Cancer Progression by Noncoding RNAs.
CONCLUSION: These ncRNAs play critical roles in cell growth, cell cycle regulation, epithelial-mesenchymal transition (EMT), invasion, migration, and apoptosis among others, and were observed to be highly dysregulated in several cancers. The miRNAs and lncRNAs were observed to interact with each other through several mechanisms that governed the expression of their respective targets and could act either as tumor suppressors or as oncogenes, playing a crucial part in breast carcinogenesis. PMID: 32652909 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - July 11, 2020 Category: Cancer & Oncology Authors: Akshaya RL, Rohini M, Selvamurugan N Tags: Curr Cancer Drug Targets Source Type: research

Targeting NUPR1 for Cancer Treatment: A Risky Endeavor.
Abstract NUPR1 is a transcription factor that has attracted great attention because its various roles in cancer. Several studies were carried out to determine its molecular targets and mechanism of action to develop novel therapies against cancer. Here, we shed light on the role of NUPR1 in different types of cancer. NUPR1 regulates a complex network of pathways that may be affected by its silencing, which can cause varying effects. Its role in some types of cancer has been reported but remains incompletely understood whereas its roles in other types of cancers have not been reported yet. Therefore, targeting NUPR...
Source: Current Cancer Drug Targets - July 2, 2020 Category: Cancer & Oncology Authors: Mansour SMA, Ali SA, Nofal S, Soror SH Tags: Curr Cancer Drug Targets Source Type: research

Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
CONCLUSION: In patients with metastatic colorectal cancer, selinexor on this dose schedule plus mFOLFOX6 was not tolerable. Other dosing schedules or combinations may be evaluated. Clinical trial identifier NCT02384850. PMID: 32598257 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - June 26, 2020 Category: Cancer & Oncology Authors: Nilsson S, Stein A, Rolfo C, Kranich A, Mann J, Papadimitriou K, Theile S, Amberg S, Bokemeyer C Tags: Curr Cancer Drug Targets Source Type: research

Emerging Multi-Cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT.
Abstract RNA binding proteins (RBPs) associate with nascent and mature RNAs to perform biological functions such as alternative splicing and RNA stability. Having unique RNA recognition binding motifs, RBPs form complexes with RNA in a sequence- and structure-based manner. Aberrant expressions of several RBPs have been identified in tumorigenesis and cancer progression. These uncontrolled RBPs affect several mechanisms, including cell proliferation, tumor growth, invasion, metastasis and chemoresistance. Epithelial splicing regulatory protein 1 (ESRP1) is a member of the hnRNP family of proteins that play a crucia...
Source: Current Cancer Drug Targets - June 20, 2020 Category: Cancer & Oncology Authors: Vadlamudi Y, Dey DK, Kang SC Tags: Curr Cancer Drug Targets Source Type: research

The Roles of Alternative Splicing in Tumor-immune Cell Interactions.
Abstract Alternative splicing (AS) plays a significant role in the hallmarks of cancer and can provide neoantigens for immunotherapy. Here, we summarize recent advances in immune system associated tumor specific-antigens (TSAs) produced by AS. We further discuss the regulating mechanisms involved in AS-mediated innate and adaptive immune responses and the anti-tumoral and pro-tumoral roles in different types of cancer. For example, ULBP1_RI, MLL5△21spe, NKp44-1△5, MHC-I△7, CD200S△1, 2, PVR α/β/γ/δ and IL-33 variants 1/2/3 act as regulators in solid tumors and IPAK4-L and, FOXP1&Delta...
Source: Current Cancer Drug Targets - June 18, 2020 Category: Cancer & Oncology Authors: Wang Y, Zhang H, Jiao B, Nie J, Li X, Wang W, Wang H Tags: Curr Cancer Drug Targets Source Type: research

Targeting MUC15 Protein in Cancer: Molecular Mechanisms and Therapeutic Perspectives.
Abstract MUC15, a member of the mucin family, is a heavily glycosylated transmembrane protein with the primary functions of lubricating surfaces, establishing a selective molecular barrier at the epithelium and mediating signal transduction. Aberrant expression of MUC15 plays a crucial role in the progression of multiple diseases including malignant tumors. MUC15 has been identified as a tumor suppressor, but current evidences indicate that its function as an oncogene in different types of cancers. MUC15 has been shown to be involved in the development of cancer and influence cellular growth, adhesion, invasion, m...
Source: Current Cancer Drug Targets - May 31, 2020 Category: Cancer & Oncology Authors: Zhang S, Zhang W, Xiao Y, Qin T, Yue Y, Qian W, Shen X, Ma Q, Wang Z Tags: Curr Cancer Drug Targets Source Type: research

Immune checkpoint inhibitors in patients with recurrent hepatocellular carcinoma after liver transplantation: one case report and literature review.
CONCLUSIONS: This novel drug might be a useful method to allow doctors to guarantee a better chance for long-term survival in recurrent, metastatic HCC patients with previous LT. However, it should be used with caution in allograft recipients due to the risk of acute graft rejection, further larger, prospective studies are needed to determine optimal immunomodulatory therapy to achieve optimal anti-tumor efficacy with transplant liver preservation. PMID: 32433005 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 18, 2020 Category: Cancer & Oncology Authors: Qiu J, Tang W, Du C Tags: Curr Cancer Drug Targets Source Type: research

FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
Abstract Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in 30% of acute myeloid leukaemia (AML) patients at diagnosis and confer an adverse clinical prognosis. Mutated FLT3 has emerged as a viable therapeutic target and a number of FLT3-directed tyrosine kinase inhibitors have progressed through clinical development over the last 10-15 years. The last two years have seen United States Food and Drug Administration (US FDA) approvals of the multi-kinase inhibitor midostaurin for newly-diagnosed FLT3-mutated patients when used in combination with intensive chemotherapy, and of the more FLT3-sel...
Source: Current Cancer Drug Targets - May 16, 2020 Category: Cancer & Oncology Authors: Hogan FL, Williams V, Knapper S Tags: Curr Cancer Drug Targets Source Type: research

CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia.
CONCLUSION: These findings indicate that polymorphic CYP1A1 and CYP2D6 genes affect the susceptibility to CML. PMID: 32418524 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 16, 2020 Category: Cancer & Oncology Authors: Idris HM, Khalil HB, Mills J, Elderdery AY Tags: Curr Cancer Drug Targets Source Type: research

Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Abstract Triple negative breast cancer (TNBC) is one of the most aggressive subtype of breast cancer accounting for 15-20% of cases and is defined by the lack of hormonal receptors viz., estrogen receptor (ER), progesterone receptor (PR) and expression of human epidermal growth receptor 2 (HER2). Treatment of TNBC is more challenging than other subtypes of breast cancer due to the lack of markers for the molecularly targeted therapies (ER, PR, and HER-2/ Neu), the conventional chemotherapeutic agents are still the mainstay of the therapeutic protocols of its patients. Despite, TNBC being more chemo-responsive than...
Source: Current Cancer Drug Targets - May 16, 2020 Category: Cancer & Oncology Authors: Mir M, Khan H, Mehraj U, Nisar S, Bhat B, Wani N Tags: Curr Cancer Drug Targets Source Type: research

Strategic combination therapies for ovarian cancer.
Abstract Ovarian cancer remains the leading cause of gynecologic cancer-related death among women worldwide. The dismal survival rate is partially due to recurrence after standardized debulking surgery and first-line chemotherapy. In recent years, targeted therapies including antiangiogenic agents or poly (ADP-ribose) polymerase inhibitors represent breakthroughs in the treatment for ovarian cancer. As more therapeutic agents become available supplemented by deeper understanding of ovarian cancer biology, a range of combination treatment approaches are being actively investigated to further improve the clinical ou...
Source: Current Cancer Drug Targets - May 9, 2020 Category: Cancer & Oncology Authors: Li X, Angel Sn Ng, Mak VC, Chan KK, Cheung AN, Cheung LW Tags: Curr Cancer Drug Targets Source Type: research

Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.
CONCLUSION: Hepatitis C virus infection is an independent prognostic factor for EFS and OS in diffuse large B-cell lymphoma. HCV treatment is associated with higher EFS and OS but can't be consider as an independent prognostic factor. PMID: 32392114 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 9, 2020 Category: Cancer & Oncology Authors: Elbedewy TA, A Elashtokhy HE, Abd-Elsalam S, Suliman MA Tags: Curr Cancer Drug Targets Source Type: research

Targeted drug therapy to overcome chemoresistance in Triple Negative Breast Cancer.
Abstract Triple Negative Breast Cancer (TNBC) is the most aggressive and prevailing breast cancer subtype. The chemotherapeutics used in the treatment of TNBC suffer with chemoresistance, dose limiting toxicities and off-target side effects. As a result, conventional chemotherapeutics are unable to prevent tumor growth, metastasis and result in failure of therapy. Various new targets such as BCSCs surface markers (CD44, CD133, ALDH1), signaling pathways (IL-6/JAK/STAT3, notch), pro and anti-apoptotic proteins (Bcl-2, Bcl-xL, DR4, DR5), hypoxic factors (HIF-1α, HIF2α) and drug efflux transporters (ABCC1...
Source: Current Cancer Drug Targets - May 5, 2020 Category: Cancer & Oncology Authors: Kumari M, Krishnamurthy PT, Sola P Tags: Curr Cancer Drug Targets Source Type: research

Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells.
Abstract Tumor recurrence and drug resistance are two of the key factors affecting the prognosis of cancer patients. Cancer stem cells (CSCs) are a group of cells with infinite proliferation potential which are not sensitive to traditional therapies including radio- and chemotherapy. These CSCs are considered to be central to tumor recurrence and the development of drug resistance. In addition, CSCs are important targets in cancer immunotherapy because of their expression of novel tumor-associated antigens, which result from mutations in cancer cells over the course of treatment. Emerging immunotherapies, includin...
Source: Current Cancer Drug Targets - May 3, 2020 Category: Cancer & Oncology Authors: Wang W, Bai L, Xu D, Li W, Cui J Tags: Curr Cancer Drug Targets Source Type: research

Cancer Stem Cells with Overexpression of Neuronal Markers Enhance Chemoresistance and Invasion in Retinoblastoma.
CONCLUSION: We have demonstrated neural stem cell/CSC markers that facilitate the maintenance of cancer stem cells. Developing therapies targeting these factors will help in overcoming resistance and improving retinoblastoma treatment. PMID: 32364077 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 3, 2020 Category: Cancer & Oncology Authors: Balaji S, Santhi R, Kim U, Muthukkaruppan V, Priya CG, Vanniarajan A Tags: Curr Cancer Drug Targets Source Type: research

HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of Gastric Cancer to Trastuzumab.
CONCLUSION: HOTAIR can not only promote tumor proliferation, but also enhances the resistance of tumor cells to drugs. Our experimental data not only showed strong expression of HOTAIR in gastric cancer, but also that strong expression of HOTAIR caused the sensitivity of gastric cancer cells to trastuzumab, which is a useful reference for postoperative medication. PMID: 32364078 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 3, 2020 Category: Cancer & Oncology Authors: Bie L, Luo S, Li D, Wei Y, Mu Y, Chen X, Wang S, Guo P, Lu X Tags: Curr Cancer Drug Targets Source Type: research

USP48 Sustains Chemoresistance and Metastasis in Ovarian Cancer.
Abstract Ubiquitin specific protease 48 (USP48) is a member of the deubiquitinating enzymes (DUBs) family. However, the function of USP48 in ovarian cancer remains unclear. The present study reveals that USP48 knockdown could significantly inhibit cell migration and invasion in ES2, 3AO and A2780 cells, without affecting cell proliferation. After carboplatin (CBP) treatment, the USP48 ablation increases the apoptosis rate, and the cleaved PARP and cleaved caspase 3 expression levels in ES2, 3AO and A2780 cells. The subcutaneous tumor and intraperitoneally injected experiments demonstrated that the USP48 knockdown ...
Source: Current Cancer Drug Targets - May 1, 2020 Category: Cancer & Oncology Authors: Lei X, Li X, Chen H, Liu Z Tags: Curr Cancer Drug Targets Source Type: research

Vaccine and Cell Based Therapeutic Approaches in Acute Myeloid Leukemia.
Abstract Over the past decade, our increased understanding of the interactions between the immune system and cancer cells has led to paradigm shifts in the clinical management of solid and hematologic malignancies. The incorporation of immune-targeted strategies into the treatment landscape of acute myeloid leukemia (AML), however, has been challenging. While this is in part due to the inability of the immune system to mount an effective tumor-specific immunogenic response against the heterogeneous nature of AML, the decreased immunogenicity of AML cells also represents a major obstacle in the effort to design eff...
Source: Current Cancer Drug Targets - April 30, 2020 Category: Cancer & Oncology Authors: Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, Zaid MA, Farag SS, Konig H Tags: Curr Cancer Drug Targets Source Type: research